A Phase 1 clinical trial of Roche's licensed product candidate 4D-110, administered by a single intravitreal injection for choroidemia, will begin, according to 4D Molecular Therapeutics, lead developer of clinical-stage precision. The first patient in the trial was dosed. The AAV gene medicine controlled based on directed evolution. A genetic retinal disease called choroideremia, which causes blindness and is currently incurable, is inherited in an X-linked manner.
Kiora Pharmaceuticals has been approved to treat up to six other patients in the ABACUS study KIO301, for which it obtained an investigational new medicinal product approval in Australia. Initially, ABACUS was designed for the purpose of evaluating patients with retinitis pigmentosa. Kiora applied for this approval to evaluate additional patients with late stage RP as well as those with late stage Choroideremia, a rare form of hereditary retinal degeneration, on the basis of encouraging results shared.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5519
Published Date: Jan 08, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of choroideremia and growing advancement in medical technology are some of the major factors anticipated to drive the growth of the choroideremia treatment market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.
The major players in the market are of Biogen, Copernicus Therapeutics, Inc., 4D Molecular Therapeutics, Wize Pharma Inc., Retina Implant AG, Hoffmann-La Roche Ltd, and others.
The opthalmic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.